Summit on the Future Treatments in Hemophilia

To address the increasing costs associated with treating patients with hemophilia, and in light of emerging treatment options for managing patients, AMCP convened an expert forum of stakeholders. Forum participants included representatives from regional and national health plans, integrated delivery networks, 340b entities, pharmacy benefit managers, specialty pharmacies, and patient advocacy organizations (Figure 1). Participants discussed the evolving role of factor, inhibitor management, the emergence of nonfactor treatments pipeline therapies (including gene therapy) and the impact of new treatments on the delivery of care.
 

• Findings from the Summit on the Future Treatments in Hemophilia
• Webinar